Combined cannabinoid therapy via an oromucosal spray.

Author(s): Perez J

Department of Anesthesia, Chronic Pain Unit, Hospital Clinic de Barcelona, Barcelona, Spain. [email protected]

Subject: General View the study


Extensive basic science research has identified the potential therapeutic benefits of active compounds extracted from the Cannabis sativa L. plant (the cannabinoids). It is recognized that a significant proportion of patients suffering with the debilitating symptoms of pain and spasticity in multiple sclerosis or other conditions smoke cannabis despite the legal implications and stigma associated with this controlled substance. GW Pharmaceuticals have developed Sativex (GW- 1,000-02), a combined cannabinoid medicine that delivers and maintains therapeutic levels of two principal cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), via an oromucosal pump spray, that aims to minimize psychotropic side effects...

Source: Drugs Today (Price: $95)
Share Tweet

More medical studies related to General:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.

анаполон курс

еще по теме